Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

Completed · Not applicable

Conditions studied: Type 2 Diabetes, Cardiovascular Diseases

In brief

The purpose of this study is to learn more about using a proteomic test called the SomaSignal Cardiovascular (CV) Risk Test in Type 2 Diabetes (CVD-T2D) to improve medical care for patients.

Key facts

Study ID

NCT05166382

Run by

University of Colorado, Denver

People needed

350

Starts

2022-01-01

Expected to finish

2024-01-01

Last updated by the study team

2025-03-20

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Use of SGLT2i , GLP1RA and PCSK9i within the 3 months prior to enrollment
• Systemic Lupus Erythematous (SLE)*
• Pregnancy (as determined by self report)
• Intolerance or contraindication for use of both GLP1RA and SGLT2i
• History of, an active, or untreated malignancy, in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years prior to, or are receiving or planning to receive therapy for cancer, at screening
• Samples provided by patients with SLE may fail to produce results or may produce inaccurate results because autoantibodies in the patient plasma may interact with the DNA-based reagents used in the assay

Where it is running

• Aanchal Gupta — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.